Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
JUPITER, Fla. - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), a biopharmaceutical company with a market capitalization of $2.94 billion and impressive revenue growth of 40.5% over the last twelve months, announced Monday its intention to offer $400 million in convertible senior notes due 2030 to qualified institutional buyers in a private placement under Rule 144A of the Securities Act. According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet.
The biopharmaceutical company also plans to grant initial purchasers a 13-day option to buy up to an additional $60 million in notes. The notes will be general unsecured, senior obligations with semiannual interest payments beginning April 1, 2026, and maturing October 1, 2030. The company’s strong liquidity position is evidenced by its current ratio of 5.45, indicating ample ability to meet short-term obligations.
Upon conversion, Ligand will pay cash up to the principal amount and may deliver cash, shares, or a combination for any remainder of the conversion obligation. The interest rate and conversion rate will be determined at pricing.
Ligand expects to use part of the proceeds for convertible note hedge transactions, up to $30 million to repurchase shares from certain note purchasers in private transactions, and the remainder for general corporate purposes.
In connection with the offering, Ligand plans to enter into convertible note hedge transactions and warrant transactions with option counterparties, which could affect the market price of Ligand’s common stock and the notes.
The notes and warrants will only be offered to qualified institutional buyers under Rule 144A and have not been registered under the Securities Act, limiting their sale in the United States.
Ligand describes itself as a biopharmaceutical company that enables scientific advancement by supporting clinical development of medicines through financing, technology licensing, or both. The company’s stock has shown remarkable strength, trading near its 52-week high of $151.55, with a significant return of over 33% in the past six months. For deeper insights into Ligand’s financial health and growth prospects, investors can access comprehensive analysis through InvestingPro, which offers exclusive access to 14+ additional ProTips and detailed valuation metrics.
The information is based on a company press release statement.
In other recent news, Ligand Pharmaceuticals reported impressive financial results for the second quarter of 2025, with total revenue reaching $47.6 million. This represents a 15% year-over-year growth and exceeded consensus estimates by approximately 9%. The revenue increase was largely driven by strong performance in the Royalty and Captisol segments. Additionally, Ligand’s adjusted earnings per share (EPS) stood at $1.60, surpassing the forecasted $1.43, marking an 11.89% surprise. Following these results, RBC Capital raised its price target for Ligand to $185 from $155, maintaining an Outperform rating. Similarly, Oppenheimer increased its price target to $167 from $162, also maintaining an Outperform rating. Oppenheimer highlighted the strong growth in royalty revenue, which reached $36.4 million, representing a 57% year-over-year increase. These developments reflect a positive outlook from analysts regarding Ligand’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.